Camella Wilson, Ph.D.

Camella Wilson is a Principal at Northpond Ventures. Cammie supports Northpond’s origination, sourcing, diligence, and monitoring efforts. She is a board observer at Aro Biotherapeutics, Octave Bioscience, and Ansa Biotechnologies and leads Northpond’s partnerships with Merck Digital Science Studio and General Inception. Previously, Cammie was an Investment Associate at OCV Partners and focused on companies enabling precision medicine across biotech, medtech, and digital health. Earlier, she was a consultant at Boston Consulting Group, supporting global pharmaceutical and consumer companies in achieving strategic and operational objectives. Cammie conducted her postdoctoral studies at University of California, San Francisco. She was also an Adjunct Assistant Professor at Temple University where she taught biology and genetics. Cammie earned a Ph.D. in biochemistry and molecular biophysics from the University of Pennsylvania. She graduated summa cum laude with honors from Temple University, receiving a B.S. in biochemistry.